Longitudinal BRAF monitoring showed that, a reduction in AF at 4 and 12 weeks after commencing treatment was significantly associated with longer PFS and OS, indicating that an early drop in cfBRAFV600E levels could be predictive of survival when monitoring advanced stage cancers using cfDNA. Here, BRAF is linked to atrial fibrillation.